The drugs in this trial – NZV930, PDR001 and NIR178 – are experimental immunotherapies that work by reactivating the body’s own immune response to target and destroy cancer cells.
PDR001 works in a similar fashion to other approved immunotherapies such as pembrolizumab (Keytruda®). Meanwhile, NZV930 and NIR178 work by targeting a new potential cancer-target called adenosine.
These drug names are just placeholders provided by the pharmaceutical company for the duration of the trial.
This study will investigate the safety and effectiveness of NZV930 used by itself, as well as in the combination of NZV930 with PDR001 and/or NIR178. Accordingly, you may be enrolled on any one of four treatment groups:
- NZV930 alone
- NZV930 with PDR001
- NZV930 with NIR178
- NZV930 with NIR178 & PDR001
This study is specifically designed for patients with advanced kidney cancer who have completed standard therapy and whose cancer has continued to grow despite treatment.
- All subtypes eligible
- Cancer has spread or cannot be removed by surgery
- Must have completed all standard therapies (no further drugs are available)
- Must be able and willing to undergo a tumour biopsy
Additional eligibility criteria will apply. Please speak to your doctor.
Find out more about this study.
|Hospital / Cancer Centre||Principal Investigator||Location||Trial Status|
|Hospital / Cancer CentrePrincess Margaret Cancer Centre||Principal InvestigatorNot given||LocationToronto, ON||Trial StatusRecruiting|
|Hospital / Cancer CentreNovartis Investigative Site - Quebec||Principal Investigator||LocationMontreal, QB||Trial StatusRecruiting|